Dopamine-Derived Neurotoxicity and Parkinson's Disease

Endogenous Toxins: Targets for Disease Treatment and Prevention

Volumn , Issue , 2010, Pages 695-714

  Labandeira garcia, Jose Luis ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Dopamine neurotoxicity; Huntington's disease; L 3,4 dihydroxy phenylalanine; Neurodegeneration; Oxidative stress; Parkinson's disease

Indexed keywords

EID: 84885009455     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527628100.ch28     Document Type: Chapter

References (134)

1. Carlsson, A., Falck, B., and Hillarp, N.A. (1962)Cellular localization of brain monoamines. Acta Physiol Scand Suppl,56, 1-28.
2. Eisenhofer, G., Kopin, I.J., and Goldstein, D.S. (2004)Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev,56, 331-349.
3. Carlsson, A. (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev, 11, 490-493.
4. Hughes, A.J., Daniel, S.E., Kilford, L., and Lees, A.J. (1992)Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry,55, 181-184.
5. Bergman, H. and Deuschl, G. (2002) Pathophysiology of Parkinson's disease: from clinical neurology to basic neuroscience and back. Mov Disord, 17 (Suppl 3), 28-40.
6. Olanow, C.W. (2007) The pathogenesis of cell death in Parkinson's disease. Mov Disord, 22 (Suppl 17), S335-S342.
7. Berg, D., Youdim, M.B., and Riederer, P. (2004)Redox imbalance. Cell Tissue Res,318, 201-213.
8. Andersen, J.K. (2004) Oxidative stress in neurodegeneration: cause or consequence. Nat Med, 10, S18-S25.
9. Olanow, C.W. (1990) Oxidation reactions in Parkinson's disease. Neurology, 40 (Suppl 3), 32-39.
10. Fahn, S. and Cohen, G. (1992)The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol,32, 804-812.
11. Offen, D., Hochman, A., Gorodin, S., Ziv, I., Shirvan, A., Barzilai, A., and Melamed, E. (1999)Oxidative stress and neuroprotection in Parkinson's disease: implications from studies on dopamine-induced apoptosis. Adv Neurol,80, 265-269.
12. Barzilai, A., Melamed, E., and Shirvan, A. (2001) Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease? Cell Mol Neurobiol, 21, 215-235.
13. Ahlskog, J.E. (2007)Beating a dead horse: dopamine and Parkinson disease. Neurology,69, 1701-1711.
14. Lang, A.E. and Obeso, J.A. (2004)Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol,55, 761-765.
15. Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A., Jansen Steur, E.N., and Braak, E. (2003)Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging,24, 197-211.
16. Braak, H., Bohl, J.R., Müller, C.M., Rüb, U., de Vos, R.A., and Del Tredici, K. (2006)Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord,21, 2042-2051.
17. Olanow, C.W. and Jankovic, J. (2005) Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord, 20 (Suppl 11), S3-S10.
18. Ogawa, N., Tanaka, K., and Asanuma, M. (2000)Bromocriptine markedly suppresses levodopa-induced abnormal increase of dopamine turnover in the parkinsonian striatum. Neurochem Res,25, 755-800.
19. Pardo, B., Mena, M.A., Casarejos, M.J., Paúno, C.L., and De Ýebenes, J.G. (1995) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res, 5 (682), 133-430.
20. Ogawa, N., Asanuma, M., Kondo, Y., Kawada, Y., Yamamoto, M., and Mori, A. (1994) Differential effects of chronic L-dopa treatment on lipid peroxidation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci Lett, 25 (171), 55-80.
21. Müller, T., Hefter, H., Hueber, R., Jost, W.H., Leenders, K.L., Odin, P., and Schwarz, J. (2004) Is levodopa toxic? J Neurol, 251 (Suppl 6), VI/44-VI/46.
22. Datla, K.P., Blunt, S.B., and Dexter, D.T. (2001)Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord,16, 424-440.
23. Mytilineou, C., Walker, R.H., JnoBaptiste, R., and Olanow, C.W. (2003)Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther,304, 792-800.
24. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., Marek, K. Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med, 9 (351), 2498-2508.
25. McGeer, P.L., Itagaki, S., Akiyama, H., and McGeer, E.G. (1988)Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol,24, 574-576.
26. Fearnley, J.M. and Lees, A.J. (1991)Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain,114, 2283-2301.
27. Kubis, N., Faucheux, B.A., Ransmayr, G., Damier, P., Duyckaerts, C., Henin, D., Forette, B., Le Charpentier, Y., Hauw, J.J., Agid, Y., and Hirsch, E.C. (2000)Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain,123, 366-373.
28. Collier, T.J., Lipton, J., Daley, B.F., Palfi, S., Chu, Y., Sortwell, C., Bakay, R.A., Sladek, J.R. Jr and Kordower, J.H. (2007)Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis,26, 56-65.
29. Villar-Cheda, B., Sousa-Ribeiro, D., Rodriguez-Pallares, J., Rodriguez-Perez, A.I., Guerra, M.J., and Labandeira-Garcia, J.L. (2009)Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease. J Cereb Blood Flow Metab, 29 (2), 230-234.
30. Sulzer, D. and Rayport, S. (1990)Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. Neuron,5, 797-808.
31. Kumar, R., Agarwal, A.K., and Seth, P.K. (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem, 64, 1703-1707.
32. Soto-Otero, R., Ḿendez-́alvarez, E., Hermida-Ameijeiras, A., Muñoz-Patiño, A., and Labandeira-Garcia, J.L. (2000)Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem,74, 1605-1612.
33. Hanrott, K., Gudmunsen, L., O'Neill, M.J., and Wonnacott, S. (2006)6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J Biol Chem,281, 5373-5382.
34. Rodriguez-Pallares, J., Parga, J.A., Muñoz, A., Rey, P., Guerra, M.J., and Labandeira-Garcia, J.L. (2007)Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem,103, 145-156.
35. Linert, W., Herlinger, E., Jameson, R.F., Kienzl, E., Jellinger, K., and Youdim, M.B.H. (1996)Dopamine, 6-hydroxydopamine, iron, dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta,1316, 160-168.
36. Glinka, Y., Gassen, M., Youdim, M.B. (1997)Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm (Suppl 50),50, 55-66.
37. Jellinger, K., Linert, L., Kienzl, E., Herlinger, E., and Youdim, M.B.H. (1995)Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm,46, 297-314.
38. Irwin, I. and Langston, J.W. (1995) Endogenous toxins as potential etiologic agents in Parkinson's disease, in Etiology of Parkinson's Disease (eds J.H. Ellenberg, W.C. Koller, and J.W. Langston), Marcel Dekker Inc., New York, pp. 153-201.
39. Senoh, S., Creveling, C.R., Udenfriend, S., and Witkop, B. (1959)Chemical, enzymatic and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc,81, 6236-6240.
40. Andrew, R., Watson, D.G., Best, S.A., Midgley, J.M., Wenlong, H., and Petty, R.K.H. (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res, 18, 1175-1177.
41. Lotharius, J. and O'Malley, K.L. (2000)The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J Biol Chem,275, 38581-38588.
42. Javitch, J.A., D'Amato, R.J., Strittmatter, S.M., and Snyder, S.H. (1985)Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A,82, 2173-2177.
43. Przedborski, S., Jackson-Lewis, V., Djaldetti, R., Liberatore, G., Vila, M., Slovodanka, V., and Almer, G. (2000)The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci,16, 135-142.
44. Obata, T. (2002)Dopamine efflux by MPTP and hydroxyl radical generation. J Neural Transm,109, 1159-1180.
45. Filloux, F. and Townsend, J.J. (1993)Pre-and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol,119, 79-88.
46. Rabinovic, A.D., Lewis, D.A., and Hastings, T.G. (2000)Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience,101, 67-76.
47. Michel, P.P. and Hefti, F. (1990)Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res,26, 428-435.
48. Daily, D., Barzilai, A., Offen, D., Kamsler, A., Melamed, E., and Ziv, I. (1999)The involvement of p53 in dopamine-induced apoptosis of cerebellar granule neurons and leukemic cells overexpressing p53. Cell Mol Neurobiol,19, 261-276.
49. Hou, S.T., Cowan, E., Dostanic, S., Rasquinha, I., Comas, T., Morley, P., and MacManus, J.P. (2001)Increased expression of the transcription factor E2F1 during dopamine-evoked, caspase-3-mediated apoptosis in rat cortical neurons. Neurosci Lett,306, 153-156.
50. Premkumar, A. and Simantov, R. (2002)Mitochondrial voltage-dependent anion channel is involved in dopamine-induced apoptosis. J Neurochem,82, 345-352.
51. Han, S.K., Mytilineou, C., and Cohen, G. (1996)L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem,66, 501-510.
52. Mena, M.A., Davila, V., and Sulzer, D. (1997)Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem,69, 1398-1408.
53. Clement, M.V., Long, L.H., Ramalingam, J., and Halliwell, B. (2002)The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem,81, 414-421.
54. Graham, D.G. (1978)Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol,14, 633-643.
55. Chen, L., Ding, Y., Cagniard, B., Van Laar, A.D., Mortimer, A., Chi, W., Hastings, T.G., Kang, U.J., and Zhuang, X. (2008)Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci,28, 425-433.
56. Erickson, J.D., Eiden, L.E., and Hoffman, B.J. (1992)Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci U S A,89, 10993-10997.
57. Miller, G.W., Erickson, J.D., Perez, J.T., Penland, S.N., Mash, D.C., Rye, D.B., and Levey, A.I. (1999)Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol,156, 138-148.
58. Caudle, W.M., Richardson, J.R., Wang, M.Z., Taylor, T.N., Guillot, T.S., McCormack, A.L., Colebrooke, R.E., Di Monte, D.A., Emson, P.C., and Miller, G.W. (2007)Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci,27, 8138-8148.
59. Caudle, W.M., Colebrooke, R.E., Emson, P.C., and Miller, G.W. (2008)Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci,31, 303-308.
60. Glatt, C.E., Wahner, A.D., White, D.J., Ruiz-Linares, A., and Ritz, B. (2006) Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet, 15, 299-305.
61. Wang, Y.M., Gainetdinov, R.R., Fumagalli, F., Xu, F., Jones, S.R., Bock, C.B., Miller, G.W., Wightman, R.M., and Caron, M.G. (1997)Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron,19, 1285-1296.
62. Mooslehner, K.A., Chan, P.M., Xu, W., Liu, L., Smadja, C., Humby, T., Allen, N.D., Wilkinson, L.S., and Emson, P.C. (2001)Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol Cell Biol,21, 5321-5331.
63. Hastings, T.G., Lewis, D.A., and Zigmond, M.J. (1996)Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A,93, 1956-1961.
64. Tse, D.C., McCreery, R.L., and Adams, R.N. (1976)Potential oxidative pathways of brain catecholamines. J Med Chem,19, 37-40.
65. Miyazaki, I. and Asanuma, M. (2008)Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta Med Okayama,62, 141-150.
66. Asanuma, M., Miyazaki, I., and Ogawa, N. (2003)Dopamine-or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res,5, 165-176.
67. Asanuma, M., Miyazaki, I., Diaz-Corrales, F.J., and Ogawa, N. (2004)Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism. Acta Med Okayama,58, 221-233.
68. Graumann, R., Paris, I., Martinez-Alvarado, P., Rumanque, P., Perez-Pastene, C., Cardenas, S.P., Marin, P., Diaz-Grez, F., Caviedes, R., Caviedes, P., and Segura-Aguilar, J. (2002)Oxidation of dopamine to aminochrome as a mechanism for neurodegeneration of dopaminergic systems in Parkinson's disease. Possible neuroprotective role of DT-diaphorase. Pol J Pharmacol,54, 573-579.
69. Choi, H.J., Kim, S.W., Lee, S.Y., and Hwang, O. (2003)Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J Neurochem,86, 143-152.
70. Korytowski, W., Sarna, T., Kalyanaraman, B., and Sealy, R.C. (1987)Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spin-stabilization and spin label oximetry. Biochim Biophys Acta,924, 383-392.
71. Rosei, M.A., Blarzino, C., Foppoli, C., Mosca, L., and Coccia, R. (1994)Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Commun,200, 344-350.
72. Hastings, T.G. (1995)Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem,6, 919-924.
73. Foppoli, C., Coccia, R., Cini, C., and Rosei, M.A. (1997)Catecholamines oxidation by xanthine oxidase. Biochim Biophys Acta,1334, 200-206.
74. Smythies, J., De Iuliis, A., Zanatta, L., and Galzigna, L. (2002)The biochemical basis of Parkinson's disease: the role of catecholamine o-quinones: a review-discussion. Neurotox Res,4, 77-81.
75. Whitehead, R.E., Ferrer, J.V., Javitch, J.A., and Justice, J.B. (2001)Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. J Neurochem,76, 1242-1251.
76. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G., and Selkoe, D.J. (2005)Dopamine covalently modifies and functionally inactivates parkin. Nat Med,11, 1214-1221.
77. Conway, K.A., Rochet, J.C., Bieganski, R.M., and Lansbury, P.T. Jr (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 294, 1346-1349.
78. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and Lansbury, P.T. Jr (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819.
79. Kuhn, D.M., Arthur, R.E. Jr, Thomas, D.M., and Elferink, L.A. (1999)Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J Neurochem,73, 1309-1317.
80. Offen, D., Ziv, I., Sternin, H., Melamed, E., and Hochman, A. (1996)Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol,141, 32-39.
81. Muñoz, A.M., Rey, P., Soto-Otero, R., Guerra, M.J. and Labandeira-Garcia, J.L. (2004)Systemic administration of N-acetylcysteine protects dopaminergic neurons against 6-hydroxydopamine-induced degeneration. J Neurosci Res,76, 551-562.
82. Zucca, F.A., Giaveri, G., Gallorini, M., Albertini, A., Toscani, M., Pezzoli, G., Lucius, R., Wilms, H., Sulzer, D., Ito, S., Wakamatsu, K., and Zecca, L. (2004)The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res,17, 610-6177.
83. Zecca, L., Mecacci, C., Seraglia, R., and Parati, E. (1992)The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta,1138, 6-10.
84. Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., and Sarna, T. (2008)Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem,106, 1866-1875.
85. Wakamatsu, K., Fujikawa, K., Zucca, F.A., Zecca, L., and Ito, S. (2003)The structure of neuromelanin as studied by chemical degradative methods. J Neurochem,86, 1015-1023.
86. Kastner, A., Hirsch, E.C., Lejeune, O., Javoy-Agid, F., Rascol, O., and Agid, Y. (1992) Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem, 59, 1080-1089.
87. Halliday, G.M., Ophof, A., Broe, M., Jensen, P.H., Kettle, E., Fedorow, H., Cartwright, M.I., Griffiths, F.M., Shepherd, C.E., and Double, K.L. (2005)Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Brain,128, 2654-2664.
88. Hirsch, E., Graybiel, A.M., and Agid, Y.A. (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 334, 345-348.
89. Wakabayashi, K., Tanji, K., Mori, F., and Takahashi, H. (2007)The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates. Neuropathology,27, 494-506.
90. Zecca, L., Zucca, F.A., Wilms, H., and Sulzer, D. (2003)Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci,26, 578-580.
91. Zareba, M., Bober, A., Korytowski, W., Zecca, L., and Sarna, T. (1995)The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta,1271, 343-348.
92. Langston, J.W., Forno, L.S., Tetrud, J., Reeves, A.G., Kaplan, J.A., and Karluk, D. (1999)Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol,46, 598-605.
93. Block, M.L. and Hong, J.S. (2005) Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol, 76, 77-98.
94. Fedorow, H., Pickford, R., Kettle, E., Cartwright, M., Halliday, G.M., Gerlach, M., Riederer, P., Garner, B., and Double, K.L. (2006)Investigation of the lipid component of neuromelanin. J Neural Transm,113, 735-739.
95. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
96. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T.E., Muzyczka, N., Mandel, R.J., and Björklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci, 22, 2780-2791.
97. Kirik, D., Annett, L.E., Burger, C., Muzyczka, N., Mandel, R.J., and Björklund, A. (2003)Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A,100, 2884-2889.
98. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W., and Yankner, B.A. (2002)Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med,8, 600-606.
99. Mazzulli, J.R., Mishizen, A.J., Giasson, B.I., Lynch, D.R., Thomas, S.A., Nakashima, A., Nagatsu, T., Ota, A., and Ischiropoulos, H. (2006)Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci,26, 10068-10078.
100. Follmer, C., Romão, L., Einsiedler, C.M., Porto, T.C., Lara, F.A., Moncores, M., Weissmüller, G., Lashuel, H.A., Lansbury, P., Neto, V.M., Silva, J.L., and Foguel, D. (2007)Dopamine affects the stability, hydration, and packing of protofibrils and fibrils of the wild type and variants of alpha-synuclein. Biochemistry,46, 472-482.
101. Norris, E.H., Giasson, B.I., Hodara, R., Xu, S., Trojanowski, J.Q., Ischiropoulos, H., and Lee, V.M. (2005)Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem,280, 21212-21219.
102. Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., Trojanowski, J.Q., and Lee, V.M. (2000) Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989.
103. Lotharius, J. and Brundin, P. (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet, 11, 2395-2407.
104. Mosharov, E.V., Staal, R.G., Bov́e, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K.E., Moore, C.M., Troyer, M.D., Edwards, R.H., Przedborski, S., and Sulzer, D. (2006)Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci,26, 9304-9311.
105. Guo, J.T., Chen, A.Q., Kong, Q., Zhu, H., Ma, C.M., and Qin, C. (2008)Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol,28, 35-47.
106. Machida, Y., Chiba, T., Takayanagi, A., Tanaka, Y., Asanuma, M., Ogawa, N., Koyama, A., Iwatsubo, T., Ito, S., Jansen, P.H., Shimizu, N., Tanaka, K., Mizuno, Y., and Hattori, N. (2005)Common anti-apoptotic roles of parkin and alpha-synuclein in human dopaminergic cells. Biochem Biophys Res Commun,332, 233-240.
107. Chen, J., Wersinger, C., and Sidhu, A. (2003)Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric-oxide synthase activation and cytotoxicity. J Biol Chem,278, 28089-28100.
108. Davis, S., Brotchie, J., and Davies, I. (2002)Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia. Exp Neurol,176, 229-236.
109. Charvin, D., Vanhoutte, P., Pagès, C., Borrelli, E., and Caboche, J. (2005)Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc Natl Acad Sci U S A,102, 12218-12223.
110. Cyr, M., Beaulieu, J.M., Laakso, A., Sotnikova, T.D., Yao, W.D., Bohn, L.M., Gainetdinov, R.R., and Caron, M.G. (2003)Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A,100, 11035-11040.
111. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D., and Richardson, E.P. Jr (1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol, 44, 559-577.
112. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
113. Jakel, R.J. and Maragos, W.F. (2000)Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci,23, 239-245.
114. Ellison, D.W., Beal, M.F., Mazurek, M.F., Malloy, J.R., Bird, E.D., and Martin, J.B. (1987)Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. Brain,110, 1657-1673.
115. Klawans, H.L., Goetz, C.G., Paulson, G.W., and Barbeau, A. (1980) Levodopa and presymptomatic detection of Huntington's disease-eight-year follow-up. N Engl J Med, 302, 1090.
116. Cass, W.A. (1997)Decreases in evoked overflow of dopamine in rat striatum after neurotoxic doses of methamphetamine. J Pharmacol Exp Ther,280, 105-113.
117. Filloux, F. and Wamsley, J.K. (1991)Dopaminergic modulation of excitotoxicity in rat striatum: evidence from nigrostriatal lesions. Synapse,8, 281-288.
118. Buisson, A., Pateau, V., Plotkine, M., and Boulu, R.G. (1991)Nigrostriatal pathway modulates striatum vulnerability to quinolinic acid. Neurosci Lett,131, 257-259.
119. Kerkerian, L., Dusticier, N., and Nieoullon, A. (1987)Modulatory effect of dopamine on high-affinity glutamate uptake in the rat striatum. J Neurochem,48, 1301-1306.
120. Cepeda, C., Colwell, C.S., Itri, J.N., Chandler, S.H., and Levine, M.S. (1998)Dopaminergic modulation of NMDA-induced whole cell currents in neostriatal neurons in slices: contribution of calcium conductances. J Neurophysiol,79, 82-94.
121. Guerra, M.J., Liste, I., and Labandeira-Garcia, J.L. (1998)Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. Synapse,28, 71-82.
122. Liste, I., Muñoz, A., Guerra, M.J., and Labandeira-Garcia, J.L. (2000)Fenfluramine-induced increase in preproenkephalin mRNA levels in the striatum: interaction between the serotonergic, glutamatergic, and dopaminergic systems. Synapse,35, 182-191.
123. Morari, M., Marti, M., Sbrenna, S., Fuxe, K., Bianchi, C., and Beani, L. (1998)Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochem Int,33, 383-397.
124. Amano, T., Ujihara, H., Matsubayashi, H., Sasa, M., Yokota, T., Tamura, Y., and Akaike, A. (1994)Dopamine-induced protection of striatal neurons against kainate receptor-mediated glutamate cytotoxicity in vitro. Brain Res,655, 61-69.
125. Bozzi, Y. and Borrelli, E. (2006) Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends Neurosci, 29, 167-174.
126. Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Akaike, A., Kimura, J., and Shimohama, S. (1998)Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann Neurol,44, 110-119.
127. Takashima, H., Tsujihata, M., Kishikawa, M., and Freed, W.J. (1999) Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp Neurol, 159, 98-104.
128. Mitchell, I.J., Cooper, A.C., Griffiths, M.R., and Cooper, A.J. (2002)Acute administration of haloperidol induces apoptosis of neurones in the striatum and substantia nigra in the rat. euroscience,109, 89-99.
129. Schauwecker, P.E. and Steward, O. (1997)Genetic determinants of susceptibility to excitotoxic cell death: implications for gene targeting approaches. Proc Natl Acad Sci U S A,94, 4103-4108.
130. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. J Am Med Assoc, 287, 1653-1661.
131. Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias,C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., Poewe, W.H., Hauser, R.A., and Brooks, D.J. REAL-PET Study Group (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol, 54, 93-101.
132. Rouge-Pont, F., Usiello, A., Benoit-Marand, M., Gonon, F., Piazza, P.V., and Borrelli, E. (2002)Changes in extracellular dopamine induced by morphine and cocaine: crucial control by D2 receptors. J Neurosci,22, 3293-3301.
133. Usiello, A., Baik, J.H., Rouǵe-Pont, F., Picetti, R., Dierich, A., LeMeur, M., Piazza, P.V., and Borrelli, E. (2000)Distinct functions of the two isoforms of dopamine D2 receptors. Nature,408, 199-203.
134. Lindgren, N., Usiello, A., Goiny, M., Haycock, J., Erbs, E., Greengard, P., Hokfelt, T., Borrelli, E., and Fisone, G. (2003)Distinct roles of dopamine D2L and D2S receptor isoforms in the regulation of protein phosphorylation at presynaptic and postsynaptic sites. Proc Natl Acad Sci U S A,100, 4305-4309.